$イーグル ファーマシューティカルズ(EGRX.US)$ NEWS Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
$イーグル ファーマシューティカルズ(EGRX.US)$ NEWS Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the su...
Despite moving from losses to profitability, Eagle Pharmaceuticals' share price defies logic by keeping a downward trend. Investors should cautiously observe unresolved business challenges, especially considering the company's underperformance worse than its five-year annualized loss of 13%.
Gapping up In reaction to earnings/guidance: •$ペプシコ(PEP.US)$+2.8%,$E2オープン ペアレント ホールディングス A(ETWO.US)$+0.7% Other news: •$カンゴ(CANG.US)$+23.5% (approves special dividend of $0.50 per ordinary share or $1 per ADS) •$エル ポーロ ロコ ホールディングス(LOCO.US)$+12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program) •$KnowBe4(KNBE.US)$+11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to ...
$シーチェンジ インターナショナル(SEAC.US)$ - SeaChange Soars On Triller Merger Speculation, Trump Ties. stock breaking out. $BLU - BELLUS Health Stock Surges After Positive Data From Refractory Chronic Cough Trial. Stock almost hit double digits. Looking for break of $9 $SigmaTron インターナショナル(SGMA.US)$ - ON Friday Company reported Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. needs to hold $13 support level $イーグル ファーマシューティカルズ(EGRX.US)$ - Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020. $ルシード グループ A(LCID.US)$ - stock bouncing off $35 support as expected. Looking for break of $40 to keep moving higher.
$SigmaTron インターナショナル(SGMA.US)$ - ON Friday Company reported Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. Up 100% for the day after hours. Looking to join on early market trend. $イーグル ファーマシューティカルズ(EGRX.US)$ - Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020. $センチネルワン A(S.US)$ - stock getting multiple price target upgrades on wednesday. Hitting $50 plus as expected looking for more. $ルシード グループ A(LCID.US)$ - Stock has support at $35. If holds we can see it reverse higher or back down $33 levels. $クァンタムスケープ(QS.US)$ - stock is near the support area of $24. If held we can see a reversal to $25 plus or more.
$SigmaTron インターナショナル(SGMA.US)$- ON Friday Company reported Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. Up 100% for the day after hours. Looking to join on early market trend. $イーグル ファーマシューティカルズ(EGRX.US)$- Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020. $センチネルワン A(S.US)$- stock getting multiple price target upgrades on wednesday. Hitting $50 plus as expected looking for more. $ルシード グループ A(LCID.US)$- Stock has support at $35. If holds we can see it reverse higher or back down $33 levels. $クァンタムスケープ(QS.US)$- stock is near the support area of $24. If held we can see a reversal to $25 plus or more.
イーグル ファーマシューティカルズに関するコメント
NEWS
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
NEWS
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the su...
In reaction to earnings/guidance:
• $ペプシコ(PEP.US)$+2.8%, $E2オープン ペアレント ホールディングス A(ETWO.US)$ +0.7%
Other news:
• $カンゴ(CANG.US)$ +23.5% (approves special dividend of $0.50 per ordinary share or $1 per ADS)
• $エル ポーロ ロコ ホールディングス(LOCO.US)$ +12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program)
• $KnowBe4(KNBE.US)$ +11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to ...
- SeaChange Soars On Triller Merger Speculation, Trump Ties. stock breaking out.
$BLU
- BELLUS Health Stock Surges After Positive Data From Refractory Chronic Cough Trial. Stock almost hit double digits. Looking for break of $9
$SigmaTron インターナショナル(SGMA.US)$
- ON Friday Company reported Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. needs to hold $13 support level
$イーグル ファーマシューティカルズ(EGRX.US)$
- Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$ルシード グループ A(LCID.US)$
- stock bouncing off $35 support as expected. Looking for break of $40 to keep moving higher.
- ON Friday Company reported Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. Up 100% for the day after hours. Looking to join on early market trend.
$イーグル ファーマシューティカルズ(EGRX.US)$
- Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$センチネルワン A(S.US)$
- stock getting multiple price target upgrades on wednesday. Hitting $50 plus as expected looking for more.
$ルシード グループ A(LCID.US)$
- Stock has support at $35. If holds we can see it reverse higher or back down $33 levels.
$クァンタムスケープ(QS.US)$
- stock is near the support area of $24. If held we can see a reversal to $25 plus or more.
$イーグル ファーマシューティカルズ(EGRX.US)$ - Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$センチネルワン A(S.US)$ - stock getting multiple price target upgrades on wednesday. Hitting $50 plus as expected looking for more.
$ルシード グループ A(LCID.US)$ - Stock has support at $35. If holds we can see it reverse higher or back down $33 levels.
$クァンタムスケープ(QS.US)$ - stock is near the support area of $24. If held we can see a reversal to $25 plus or more.
まだコメントはありません